Stay updated on Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page.

Latest updates to the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page
- CheckyesterdayChange DetectedStudy record dates and last-updated timestamps were updated on 2026-03-03, 2026-02-11, and 2025-12 to reflect recent maintenance.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page now shows Revision: v3.4.2 and the prior funding notice and Revision: v3.4.1 have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check29 days agoChange DetectedAn administrative funding-status notice was added and the page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check36 days agoChange DetectedAdded a Show glossary option on the page and introduced QC metadata fields Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0. Removed the previous QC metadata items Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4.SummaryDifference0.2%

- Check50 days agoChange DetectedA minor revision label was updated from Revision: v3.3.3 to Revision: v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check72 days agoChange DetectedFooter updates: added 'Revision: v3.3.3' and removed references to 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2'.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page.